AN2 Therapeutics updates epetraborole development; Phase 1 Japan study supports 500 mg dose; EU orphan designation

AN2 Therapeutics, Inc.

Phase 1 study in Japanese volunteers (EBO-103) showed no adverse events, supports once-daily 500 mg dose for Phase 2/3.
Epetraborole exposures similar across ADH genotypes and consistent with prior Phase 1 study in non-Japanese subjects.
EU Commission granted orphan medicinal product designation for epetraborole in NTM lung disease.
Company plans to initially focus clinical development for treatment-refractory MAC lung disease on Japan and the U.S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.